The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assi… (NCT07432711) | Clinical Trial Compass
RecruitingNot Applicable
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
China100 participantsStarted 2026-03-02
Plain-language summary
Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.
Who can participate
Age range18 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;
✓. Ages 18 to 64 years old；
✓. American Society of Anesthesiologists (ASA) physical status of I-III；
✓. Glasgow Coma Scale (GCS) score of 15；
✓. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.
Exclusion criteria
✕. History of chronic pain syndrome of any cause.
✕. Patients with heart conduction block (sinus block or atrioventricular block).
✕. Patients with unstable coronary artery disease.
✕. Patients with gastric ulcer or gastric bleeding.
✕. Patients with diabetes and are being treated with insulin.
What they're measuring
1
Intravenous Morphine Equivalents of Rescue Analgesic Medications Within 48 Hours Postoperatively
✕. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.
✕. Patients with abnormal liver function: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.
✕. Patients with renal impairment (serum creatinine \> 176 µmol/L) or receiving dialysis treatment within 28 days before surgery.